A carregar...
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
Targeting mTORC1 has been thoroughly explored in cancer therapy. Following encouraging preclinical studies, mTORC1 inhibitors however failed to provide substantial benefits in cancer patients. Several resistance mechanisms have been identified including mutations of mTOR and activation of alternate...
Na minha lista:
| Publicado no: | Oxid Med Cell Longev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5322438/ https://ncbi.nlm.nih.gov/pubmed/28280521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/1726078 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|